Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $3,713,937,000 | reported | |
| FY 2024 | 2024-12-31 | $2,248,243,000 | reported | |
| FY 2023 | 2023-12-31 | $1,828,292,000 | reported | |
| FY 2022 | 2022-12-31 | $1,037,418,000 | reported | |
| FY 2021 | 2021-12-31 | $844,287,000 | reported | |
| FY 2020 | 2020-12-31 | $492,853,000 | reported | |
| FY 2019 | 2019-12-31 | $219,750,000 | reported | |
| FY 2018 | 2018-12-31 | $74,908,000 | reported | |
| FY 2017 | 2018-01-01 | $2,900,000 | reported | |
| FY 2016 | 2016-12-31 | $47,159,000 | reported | |
| FY 2010 | 2010-12-31 | $100,041,000 | reported |
Alnylam Pharmaceuticals, Inc. · CIK 1178670 · Engraved from SEC EDGAR
FY2025 figures · derived
Alnylam Pharmaceuticals, Inc. is the 22nd largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834
Latest filing Nov 17, 2026
The us-gaap concepts with the most facts on file for this company.
Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
727 managers · Quarter ended Sep 30, 2026All holders ›
86